JinMatrix Obtains US Patent for Multiplex Molecular Diagnostic Core Technology
[Asia Economy Reporter Moon Hyewon] JinMatrix announced on the 8th that it has obtained a US patent for its proprietary multiplex molecular diagnostic core technology, ‘C-Tag’.
The patented technology is a platform used in the Neoplex multiplex molecular diagnostic product line. The company explained that it is recognized as a next-generation core technology capable of advanced multiplexing, surpassing the previously known limit of up to five simultaneous analyses in conventional real-time PCR technology.
Hot Picks Today
Gwanghwamun Falls Silent After Shocking Defeat: "Can't Understand Son Heungmin's Omission from Starting Lineup"
- Another Setback After Hormuz Reopens: The Factor Holding Back 600 Oil Tankers
- "Until 2 a.m. at Karaoke Bars": Female Firefighter Who Died Before Wedding Endured Forced Drinking Parties
- Nightmare Repeats After 12 Years... Hong Myungbo's Squad Upset by 'Target Win' African Team [2026 World Cup]
- "More Expensive Than King Crab When Dried": The Secret of a Chinese Delicacy Discovered on a Front Lawn
JinMatrix is currently preparing a comprehensive respiratory virus panel rapid diagnostic product applying the C-Tag core technology to its COVID-19 diagnostic products, which are being exported to Europe, the Middle East, and other regions.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
![Under a Bombshell President, a Bombshell Adviser... Rose to Defense Chief Despite Sex Scandals [World Photo]](https://cwcontent.asiae.co.kr/asiaresize/307/2026062512310523344_1782358266.png)
